ADVANCES IN THERAPY治疗进展
ADVANCES IN THERAPY(英文缩写 ADV THER),ISSN 0741-238X,eISSN 1865-8652,中文译名:治疗进展 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 4.070 | Q2 |
| 2022 | 3.800 | Q2 |
| 2023 | 3.400 | Q2 |
| 2024 | 4.000 | Q1 |
| 2025 | 4.700 | Q1 |
ADVANCES IN THERAPY 最新收录文献
-
1. Lateral Femoral Cutaneous Nerve Radiofrequency Ablation for the Treatment of Meralgia Paresthetica: A Retrospective Case Series.
1. 股外侧皮神经射频消融术治疗感觉异常性股痛：一项回顾性病例系列研究PMID:日期:2026-10-01Meralgia paresthetica is a chronic pain condition that is becoming more common due to increases in obesity and diabetes across the general population. This condition results from damage to or dysfunction of the lateral femoral cutaneous nerve (LFCN). Sensory dysfunction without motor impairment is a hallmark of meralgia paresthetica due to the LFCN being a sensory-only nerve. Symptoms affect the anterolateral to lateral thigh and include pain, tingling, burning, and numbness. Current management options include weight loss, loose clothing, physical therapy, oral medications, corticosteroid injections, and surgery. Radiofrequency ablation (RFA) may be a minimally invasive treatment option used before surgery. Although RFA has demonstrated efficacy for other nerve targets, there is currently insufficient evidence for LFCN RFA. The objective of this retrospective study was to add to the existing evidence by examining the safety and efficacy of thermal LFCN RFA for the treatment of meralgia paresthetica during a short-term follow-up of < 2 months. This was a single-site retrospective case series that obtained data from electronic medical records of all patients who underwent thermal LFCN RFA between 2014 and 2025. Other RFA types (cooled and pulsed) were excluded. The 10-cm visual analog scale (VAS) was used to assess pain at baseline and post-procedurally. Statistical analysis was performed using a paired t test in SPSS version 30. Thirteen cases involving eight patients were included in this analysis, three of whom underwent the procedure multiple times. VAS scores decreased from 5.77 ± 1.92 to 3.23 ± 2.09 (p = 0.007) after the procedure. A reduction in pain was noted in 9/13 cases. For patients with a reduction in pain, the mean improvement was 62.04%, and pain relief was sustained for 6.43 ± 4.65 months. There were no instances of adverse events. Our study found thermal LFCN RFA to be safe and effective for a high proportion of patients with meralgia paresthetica who have exhausted conservative management options. Future studies should include prospective data, additional parameters, larger sample sizes, and long-term fixed follow-ups.
-
2. Measuring Hunger Severity in Rare MC4R Pathway Diseases: Development and Psychometric Evaluation of the Most Hunger Item.
PMID:日期:2026-10-01Leptin receptor (LEPR) deficiency, pro-opiomelanocortin (POMC) deficiency, Bardet-Biedl syndrome (BBS), and acquired hypothalamic obesity (HO) are diseases of the melanocortin 4 receptor (MC4R) pathway that often lead to insatiable hunger and severe obesity. As targeted treatments, such as setmelanotide, emerge for these diseases, it is critical to understand treatment benefit from patients' perspectives. This study describes the development and psychometric evaluation of the Most Hunger item, a patient-reported outcome (PRO) measure assessing hunger in patients with MC4R pathway diseases. The content validity and appropriateness of the Most Hunger item were evaluated across three separate qualitative interview studies with individuals with LEPR or POMC deficiency, BBS, and acquired HO. Semistructured interviews were conducted. The psychometric evaluation assessed the reliability, validity, responsiveness, and meaningful within-patient change (MWPC) thresholds of the Most Hunger item using responses collected during phase 3 trials of setmelanotide from participants aged ≥12 years with LEPR or POMC deficiency, BBS, or acquired HO. Qualitative interview participants understood the Most Hunger item and could rate their hunger using the item. Hunger scores and patient experiences with hunger were consistent across the three patient populations; patients described an unrelenting hunger prior to treatment and an impactful reduction in hunger post treatment. The Most Hunger item had moderate to good test-retest reliability, and convergent correlations supported its validity. Among patients with LEPR or POMC deficiency, BBS, or acquired HO, MWPC thresholds for Most Hunger (0-10 response scale) were estimated as 1.5-2.6, 0.95-1.6, and 2.4-3.7, respectively. Individuals with these distinct MC4R pathway diseases experience similar and high levels of hunger severity, with behaviors consistent with hyperphagia. The Most Hunger item is a fit-for-purpose PRO measure of hunger to assess treatment benefit in patients aged ≥12 years with LEPR or POMC deficiency, BBS, or acquired HO. ClinicalTrials.gov identifiers, NCT03287960, NCT02896192, NCT03746522, and NCT05774756.
-
3. Real-World Treatment Patterns in Patients with Spinal Muscular Atrophy Receiving Multiple Disease-Modifying Therapies.
PMID:日期:2026-09-26Nusinersen (approved in 2016), onasemnogene abeparvovec (intravenous infusion [OAV], 2019; intrathecal injection, 2025), and risdiplam (2020) are disease-modifying therapies (DMTs) available in the US for spinal muscular atrophy (SMA). Real-world evidence on treatment patterns among patients receiving multiple DMT types remains limited. This retrospective study used the Komodo Health Research Database (2016-2024) to identify patients with SMA treated with DMTs. First DMT distribution and the proportion of patients receiving a second DMT were described for patients who initiated any DMT at age ≤ 2 years in 2022-2024 (following widespread newborn screening [NBS]). Patient characteristics, treatment sequences, and time between DMT initiations were described for patients with multiple DMTs whose first was initiated on/after May 2019, including subgroups receiving first DMT at age ≤ 2 years in 2022-2024. Among patients who initiated any DMT at age ≤ 2 years in 2022-2024 (N = 257), 64.6% started with OAV, 24.9% with risdiplam, and 10.5% with nusinersen. Of these, 12.0%, 20.3%, 55.6% of patients treated with OAV, risdiplam, and nusinersen, respectively, received a second DMT. Among patients receiving multiple DMTs during 2019-2024 (N = 341), 75.4% first initiated nusinersen, 15.2% risdiplam, and 9.4% OAV; mean age at first DMT was 15.4 years overall (17.3, 15.2, and 0.8 years, respectively). Median time from first to second DMT was 18.9 months overall. Within this cohort, 44 patients initiated their first DMT at age ≤ 2 years in 2022-2024; OAV was the most common first DMT. All patients treated with risdiplam and most patients treated with nusinersen received OAV as their second DMT; median time from first to second DMT was 13.4 months. Following widespread NBS, OAV had the highest utilization among patients age ≤ 2 years as first or second DMT after nusinersen or risdiplam. Use of a second DMT type was lowest among patients who initiated OAV.
-
4. Acute Tolerability and Long-Term Surveillance of Fecal Microbiota Transplantation in Children with Autism: A Real-World Study of 604 Procedures.
PMID:日期:2026-09-24Fecal microbiota transplantation (FMT) is a promising adjunctive therapy for autism spectrum disorder (ASD), yet comprehensive, real-world safety data in pediatric populations remain limited. This study aimed to systematically evaluate the safety profile, temporal kinetics, and risk factors for adverse events (AEs) following FMT in children with ASD. We conducted a longitudinal observational study of 224 children with ASD (aged 2-17 years) who underwent a total of 604 FMT procedures. Interventions were administered via oral capsules (Caps), nasojejunal tube (NJT), or transendoscopic enteral tube (TET). AEs were systematically graded using common terminology criteria for AEs (CTCAE) criteria, and a multivariate generalized estimating equations (GEE) model was used to identify independent risk factors. In our study, the overall incidence of AEs across 604 procedures was low at 2.5% (15/604 procedures). All documented AEs had an acute onset (< 48 h post-procedure), were strictly Grade 1 (mild) in severity, and spontaneously resolved (median duration 28.0 h). The most frequent symptoms were vomiting and irritability, with no severe or long-term AEs observed. Delivery route significantly impacted safety, and TET exhibited the highest AE rate (26.3%), whereas Caps (1.7%) and NJT (1.8%) demonstrated favorable tolerability. Multivariate analysis identified TET as the independent risk factor for AEs (adjusted odds ratio 21.90, P < 0.001). FMT demonstrates favorable acute tolerability in children with ASD, with long-term longitudinal surveillance showing no delayed adverse outcomes. Oral capsules are associated with a low AE rate and represent a preferred delivery route. Chinese Clinical Trial Registry, ChiCTR2200055943. Registered 28 January 2022, http://www.chictr.org.cn .
-
5. Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HZBio1 in Chinese Healthy Subjects: A Randomized Phase 1a Study.
PMID:日期:2026-09-24Polyethylene glycol-modified (PEGylated) recombinant uricase is a promising guideline-recommended treatment for hyperuricemia and gout. This first-in-human, single ascending dose, phase 1a trial evaluated the tolerability, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of HZBio1 in Chinese healthy subjects. The present study enrolled healthy subjects (aged 18-45 years) between March 8, 2021 and January 14, 2022. Thirty subjects were randomly assigned into 5 HZBio1 cohorts (6 per dose cohort) following the dose escalation scheme, and 10 received placebo. Each subject received a single dose of HZBio1 (in the range 0.96-12 mg) or placebo, by intramuscular injection. All treatment-emergent adverse events (TEAEs) were grade 1 or 2 in severity during a 35-day follow-up period. The TEAEs and drug-related TEAEs incidences were 76.7% versus 60.0% and 73.3% versus 60.0% in the HZBio1 and placebo cohorts, respectively. HZBio1 exposure increased in a greater than dose-proportional manner following single-dose administration across the 3- to 12-mg range. Plasma uric acid levels decreased following a single dose of HZBio1 and reached the nadir at 144-192 h. The reduction in uric acid concentration was most pronounced in the 9- to 12 mg HZBio1 cohorts. HZBio1 administration elicited low-titer anti-PEG (IgG, IgM) antibodies, whereas antidrug antibodies were rarely detected, and no subjects developed neutralizing antibodies. HZBio1 at doses of 3-12 mg was well tolerated in healthy subjects, had an acceptable pharmacokinetics profile, and promising urate-lowering effect. ClinicalTrials.gov identifier, NCT04765995.
-
6. Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study.
PMID:日期:2026-09-24Trastuzumab biosimilar EG12014 (Herwenda; EirGenix/Sandoz) was approved by the European Medicines Agency (EMA) in 2023. We aim to demonstrate equivalent efficacy, and to compare safety, immunogenicity, and pharmacokinetic (PK) profiles, of EG12014 and reference trastuzumab (ref-TRA) in early breast cancer (EBC). This Phase III, randomized, multicenter, double-blind study included adult patients with EBC. In the neoadjuvant phase, patients received epirubicin and cyclophosphamide for four cycles, then were randomized (1:1) to four cycles of EG12014 or ref-TRA (loading/maintenance dose: 8/6 mg/kg) with paclitaxel. Following surgery, patients continued adjuvant EG12014, or were rerandomized (1:1) from ref-TRA to ref-TRA or EG12014. Patients completed 12 months of treatment. The primary endpoint was centrally-assessed pathological complete response (pCR; defined as ypT0/is ypN0) at the time of surgery. Additional efficacy, safety, immunogenicity, and PK endpoints were evaluated. In the neoadjuvant phase, 405 and 402 patients were randomized to EG12014 and ref-TRA, respectively. In the adjuvant phase, 386 patients continued EG12014, 188 continued ref-TRA, and 188 switched from ref-TRA to EG12014. The primary objective, to demonstrate equivalent efficacy between EG12014 and ref-TRA, was achieved: the risk difference between treatment arms in pCR rate was - 0.004 (95% CI - 0.072 to 0.065), with the 95% CI entirely within the predefined equivalence margin of - 0.13 to 0.13 (EMA requirement). Equivalence was also demonstrated regarding the risk ratio, with a relative risk of 0.992 (90% CI 0.880-1.118) and the 90% CI completely within the predefined equivalence margin of 0.741-1.349 (US Food and Drug Administration requirement). Secondary efficacy endpoints, including overall response prior to surgery and overall survival, were also comparable between treatments. Safety, immunogenicity and PK profiles were comparable between treatments and were not impacted by switching. Trastuzumab biosimilar EG12014 and ref-TRA have equivalent efficacy, and comparable safety, immunogenicity, and PK profiles, in patients with EBC. Clinical trial registration NCT03433313; EudraCT Number 2017-003973-33.
-
7. Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease.
7. 每周一次司美格鲁肽与磺脲类、DPP4抑制剂和噻唑烷二酮类药物在2型糖尿病合并慢性肾病患者中的比较有效性PMID:日期:2026-09-23Once-weekly (OW) semaglutide has shown renal benefits in clinical trials for patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). This study compared clinical outcomes between OW semaglutide and selected oral glucose-lowering medications in real-world settings. Adults with T2D and CKD were identified from the Optum's de-identified Clinformatics Data Mart Database (01/01/2016-06/30/2023). Two samples were included: patients ineligible for or with suboptimal response to sodium-glucose cotransporter type 2 inhibitor (SGLT2i) (sample 1) and patients meeting the eligibility criteria for renal outcome analysis [sample 2; no estimated glomerular filtration rate (eGFR) < 25 mL/min/1.73 m during the 6 months before the index date and no evidence of dialysis, kidney transplantation, or kidney failure at baseline]. In sample 1, glycated hemoglobin (HbA1c), eGFR, body weight, and systolic blood pressure (SBP) were described and compared using linear mixed-effects models. In sample 2, composite renal outcome consisting of dialysis, kidney transplantation, sustained eGFR < 15 mL/min/1.73 m, or all-cause death, was evaluated and compared using Cox proportional hazard model. Using model-based estimates at 12 months, OW semaglutide was associated with greater reductions in HbA1c (- 0.54%), body weight (- 6.69 kg), SBP (- 3.63 mmHg), and greater improvement in eGFR (2.06 mL/min/1.73 m) compared to controls (all P < 0.05), with effects largely sustained during follow-up. Moreover, OW semaglutide was associated with a significantly lower risk of the composite renal outcome (adjusted hazard ratio = 0.78, 95% confidence interval: 0.62, 0.99). In real-world practice, OW semaglutide has been associated with sustained benefits in glycemic control, eGFR improvement, weight loss, and SBP reduction over selected oral glucose-lowering medications among patients with T2D and CKD who were ineligible for or with suboptimal response to SGLT2i. It has also been associated with a reduced risk of the composite renal outcome in patients meeting the eligibility criteria for the renal outcome analysis.
-
8. Correction: Sepiapterin: A Distinct, Dual Mechanism of Action that Leads to Potential Treatment Benefits Across the Spectrum of Phenylketonuria Disease Severities.
8. 更正：墨蝶呤：一种独特的作用双重机制，可在苯丙酮尿症各疾病严重程度谱系中带来潜在的治疗获益PMID:日期:2026-09-21该文献暂无摘要。
-
9. Correction to: Uncontrolled Hypertension Prevalence, Characteristic Profiles, and Risk of Cardiorenal and Metabolic Outcomes: Insights from the EnligHTN Study.
9. 更正：未控制高血压的患病率、特征谱及心肾和代谢结局风险：来自EnligHTN研究的见解PMID:日期:2026-09-21该文献暂无摘要。
-
10. Association Between Health-Related Quality of Life In Patients with Colorectal Cancer and Their Informal Caregivers.
PMID:日期:2026-09-21Cancer care increasingly relies on informal caregivers, and patients and caregivers are often managed and studied as patient-caregiver dyads. However, evidence on the association between health-related quality of life (HRQoL) in colorectal cancer patients and their caregivers remains limited. This study aimed to examine the association between patients' and caregivers' HRQoL and identify factors associated with caregivers' HRQoL. A multicenter cross-sectional study was conducted involving 119 colorectal cancer patient-caregiver dyads. HRQoL for both patients and caregivers was assessed using the EQ-5D-5L questionnaire. Descriptive analyses were performed, followed by Tobit regression to evaluate the association between patient and caregiver EQ-5D-5L utility scores and by logistic regression to examine the associations between patients' EQ-5D-5L utility scores and caregivers' HRQoL dimensions. The mean EQ-5D-5L utility score was 0.936 (SD 0.060) for caregivers and 0.747 (SD 0.263) for patients. Pain/discomfort (44.54%) and anxiety/depression (43.70%) were the most commonly reported problems among caregivers. Patients' HRQoL was positively associated with caregivers' HRQoL (p = 0.045). Patients' duration since diagnosis and clinical stage, as well as caregivers' educational level, were significantly associated with caregivers' HRQoL. Patients' EQ-5D-5L utility score was also significantly associated with caregivers' reporting of anxiety/depression (OR = 0.112, p = 0.026). HRQoL in colorectal cancer patients was significantly associated with that of their caregivers, underscoring the importance of considering both members of the patient-caregiver dyad in clinical care. These findings support routine caregiver assessment and suggest that psychologically informed supportive care may be considered in colorectal cancer nursing care and survivorship planning.